EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s

Jennifer A Hughes iD, Mauricio Pinilla, Kristina M Brooks, Ahizechukwu C Eke, Alice Stek, Brookie M Best, Mark Mirochnick, Renee Browning, Lubbe Wiesner, Kathleen George, Kevin Knowles, Petra De Koker und 8 weitere

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01498-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Jennifer A Hughes und 19 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zij…. Hauptthemen laut MEDLINE: Levofloxacin, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Treatment of rifampicin-resistant tuberculosis (RR-TB) often includes fluoroquinolones, but data on long-term exposure during and after pregnancy are limited. We examined the pharmacokinetics and safety of levofloxacin in an observational cohort of pregnant and postpartum women receiving treatment for RR-TB. METHODS: Participants were enrolled in their second or third trimester and underwent intensive pharmacokinetic sampling to quantify levofloxacin plasma concentrations at 20-26 weeks' and 30-38 weeks' gestation and at 2-8 weeks postpartum. The levofloxacin plasma concentration target was 7 µg/mL. Pharmacokinetic parameters over 12 and 24 h were described using non-compartmental analysis and within-participant comparison during pregnancy versus postpartum. Adverse events were extracted from medical records. Infants were enrolled in utero and followed on study for 4-6 months after birth. RESULTS: A total of 11 pregnant women, with a median age of 31 years, received RR-TB treatment including levofloxacin; 6 (55%) were living with HIV. In the second trimester, third trimester, and postpartum, median maximum plasma drug concentration values were 10.3, 10.6, and 10.6 µg/mL, and area under the concentration time curve over 12 h (AUC0-12) were 69.0, 77.6, and 80.2 µg·h/mL, respectively. Compared with postpartum, median AUCs were lower and clearance was higher in the second but not the third trimester. Eight (72%) women and seven (64%) infants experienced severe or life-threatening adverse events or outcomes that were unlikely to be related to levofloxacin. CONCLUSIONS: Levofloxacin AUC0-12 was lower in the second trimester than the third trimester of pregnancy and the postpartum period, but exposures overall were within target ranges. Further research is warranted to explore the clinical significance of these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinTuberculosis, Multidrug-ResistantAntitubercular AgentsPregnancy Complications, InfectiousHumansFemalePregnancyAdultRifampinPostpartum PeriodYoung AdultPregnancy Trimester, ThirdInfant, Newborn

Substanzen

LevofloxacinRifampinAntitubercular Agents

Autor:innen und Institutionen

  • Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, Cape Town, 7505, South Africa. jhughes@sun.ac.za.
  • Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA.
  • Division of Clinical Pharmacy and Department of Pediatrics, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and School of Medicine-Rady Children's Hospital San Diego, San Diego,…

ORCID-Profile: Jennifer A Hughes

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • Stellenbosch University

Zitieren

APA

Hughes, J. A., Pinilla, M., Brooks, K. M., Eke, A. C., Stek, A., Best, B. M., Mirochnick, M., Browning, R., Wiesner, L., George, K., Knowles, K., De Koker, P., Ngocho, J. S., Fairlie, L., Chakhtoura, N., Hesseling, A. C., Decloedt, E., Shapiro, D. E., van Schalkwyk, M., & IMPAACT P1026s Protocol Team (2025). Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01498-0

Vancouver

Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, et al. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01498-0

BibTeX
@article{Hughes2025,
  author = {Hughes, Jennifer A and Pinilla, Mauricio and Brooks, Kristina M and Eke, Ahizechukwu C and Stek, Alice and Best, Brookie M and Mirochnick, Mark and Browning, Renee and Wiesner, Lubbe and George, Kathleen and Knowles, Kevin and De Koker, Petra and Ngocho, James S and Fairlie, Lee and Chakhtoura, Nahida and Hesseling, Anneke C and Decloedt, Eric and Shapiro, David E and van Schalkwyk, Marije and IMPAACT P1026s Protocol Team, IMPAACT P1026s Protocol Team},
  title = {Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01498-0}
}
Kostenlos starten →